

QUESTIONS

The federal government welcomes your comments on some of the issues raised in this document to help advance thinking regarding the regulation of PGD. Further consultation will occur at a later date.

1. Are you aware of any other issues that should be addressed in the discussion of PGD?
2. In light of the issues presented above, do you feel that the Government of Canada should set boundaries for the conditions for which PGD may be used in Canada?

If yes, how should these boundaries be set. For example, do you think...

- a) that the Government should create a specific list of conditions for which PGD should be allowed.
 - b) that the Government should limit PGD to broad categories of conditions, and leave it to the Assisted Human Reproduction Agency of Canada to approve, on a case by case basis, the specific conditions for which PGD may be allowed within those broad categories;
 - c) that the Government should leave it up to the Assisted Human Reproduction Agency of Canada to decide on a case by case basis, which conditions PGD should be permitted to test for;
 - d) Or are there other options which should be considered?
3. The Government invites your views on the use of PGD for cancer predisposition testing, late onset diseases and tissue typing (HLA typing).

Please submit your comments by January 30, 2006, using the contact information below. You may also submit the following information to help us contact you in the future. Please note that all information collected is subject to the Access to Information Act and the Privacy Act so respondents may not wish to provide identifying information.

Name (optional)

Address (optional)

Email (optional)

In which stakeholder group do you belong (e.g. patient, individual born of an AHR procedure, person with a disability, physician, AHR clinic employee, other)?

Would you like to be included on AHRIO's mailing list?

Would you like to be advised of future consultation exercises concerning the AHR regulatory framework?

Send to:

The Assisted Human Reproduction Implementation Office
Health Canada, AL 7002A
Ottawa, Ontario K1A 0K9

Fax: (819) 934-1828

Email: ahr-pa@hc-sc.gc.ca